Addus HomeCare (ADUS)
(Delayed Data from NSDQ)
$128.72 USD
-4.31 (-3.24%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $128.78 +0.06 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$128.72 USD
-4.31 (-3.24%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $128.78 +0.06 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Zacks News
DaVita Inc. (DVA) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Tenet Healthcare (THC) to Sell Hospitals to Refine Portfolio
by Zacks Equity Research
Tenet Healthcare (THC) enters an agreement with Adventist Health to divest two of THC's hospitals, and continue to make Conifer's revenue cycle management services available for the divested operations.
Is Addus HomeCare (ADUS) Stock a Solid Choice Right Now?
by Zacks Equity Research
Addus HomeCare (ADUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Addus HomeCare (ADUS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Addus HomeCare (ADUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ADUS vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
ADUS vs. CHE: Which Stock Is the Better Value Option?
Addus HomeCare (ADUS) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Addus HomeCare (ADUS) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Countdown to Addus HomeCare (ADUS) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Addus HomeCare (ADUS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
4 Stocks to Watch in a Resilient Outpatient Home Health Industry
by Debanjana Dey
The rising dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry despite the macroeconomic challenges. DVA, EHC, OPCH and ADUS are well-poised to gain.
Zacks Industry Outlook Highlights DaVita, Option Care Health, Addus HomeCare and Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare and Pennant have been highlighted in this Industry Outlook article.
4 Stocks to Watch in an Evolving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, OPCH, ADUS and PNTG are well-poised to gain.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Wall Street Analysts Believe Addus HomeCare (ADUS) Could Rally 27.47%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.5% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
UnitedHealth (UNH) Unit Makes Insulin More Affordable to Avail
by Zacks Equity Research
UnitedHealth Group's (UNH) sub-unit, Optum Rx, resorts to product shift within its formulary and makes the vital medication of insulin cost-effective, thereby boosting patients' access to it.
ADUS or USPH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ADUS vs. USPH: Which Stock Is the Better Value Option?
Does Addus HomeCare (ADUS) Have the Potential to Rally 33.85% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 33.9% in Addus HomeCare (ADUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Addus HomeCare (ADUS) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Addus HomeCare (ADUS) delivered earnings and revenue surprises of 9.52% and 1.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad (BIO) Misses Q3 Earnings Estimates, Cuts 2023 View
by Zacks Equity Research
The deterioration in biopharma and early biotech customer spending and a challenging macroeconomic environment in China impact Bio-Rad's (BIO) Q3 performance.
Boston Scientific (BSX) Q3 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Boston Scientific's (BSX) organic and operational revenues at its respective core business segments and geographies rise in the third quarter.
Edwards Lifesciences (EW) Q3 Earnings Match Mark, Margins Dip
by Zacks Equity Research
Edwards Lifesciences (EW) TMTT performance benefits from the accelerated adoption of the differentiated PASCAL precision platform in the third quarter.
Integra's (IART) Q3 Earnings Miss Estimates, 2023 View Cut
by Zacks Equity Research
The impact of lost revenues and an increase in the return provision related to the Boston product recall dent Integra's (IART) Q3 revenues.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.
Can Stocks Enjoy Halloween Effect Despite Rising Rate Fear?
by Sanghamitra Saha
The spooky occasion Halloween can turn into an occasion of angels for Wall Street. Top-ranked sectors like energy, construction, medical and utilities, especially, have the potential to experience a Halloween Effect this year.
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Thermo Fisher's (TMO) PPI Business System and strong execution by its global team enabled the company to deliver strong financial performance for Q3.
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Quest Diagnostics (DGX) Tops Q3 Earnings, Gross Margin Dips
by Zacks Equity Research
Quest Diagnostics' (DGX) base business growth reflects the company's ongoing efforts to partner with health plans, hospitals and physicians amid a continued return to care.